ReviewCurrent oncology reports2020
Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Lead exposure promotes NF2-wildtype meningioma cell proliferation through the Merlin-Hippo signaling pathway.Environmental health and preventive medicine · 2025Article
- Malignant Transformation of Meningiomas.Journal of Cancer · 2025Review
- Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Coexistence of meningioma and craniofacial fibrous dysplasia: a case series of clinicopathological study and literature review.Orphanet journal of rare diseases · 2024Review
- Signaling pathways in brain tumors and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Advances and trends in meningioma research over the last decade: A scientometric and visual analysis.Frontiers in oncology · 2023Review
- Immunological role and prognostic value of somatostatin receptor family members in colon adenocarcinoma.Frontiers in pharmacology · 2023Article
- Advances in Central Nervous System Tumor Classification.Advances in experimental medicine and biology · 2023Article
- Correlation between DNA Methylation and Cell Proliferation Identifies New Candidate Predictive Markers in Meningioma.Cancers · 2022Article
- Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature.Frontiers in oncology · 2022Review
- The 100 most-cited articles on vestibular schwannoma: historical perspectives, current limitations, and future research directions.Neurosurgical review · 2021Review
- Papillary meningioma of the central nervous system: a SEER database analysis.Neurosurgical review · 2021Article
- Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss andCancers · 2021Article
- Brain Tumor Biobank Development for Precision Medicine: Role of the Neurosurgeon.Frontiers in oncology · 2021Article
- A review of advances in the last decade on targeted cancer therapy usingAmerican journal of nuclear medicine and molecular imaging · 2021Review
- World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.Frontiers in oncology · 2021Article
- PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOur understanding of the genetic and epigenetic alterations in meningioma and the underlying tumor biology of meningioma has significantly changed over the past decade and resulted in revision of prognostically relevant meningioma subclasses within and beyond the WHO classification of CNS tumors. RECENT
findingsThe 2016 WHO classification of CNS tumors recognizes WHO grade I, II, and III based on histopathological features. Recent work has identified genetic alterations with prognostic implications, including mutations of the TERT promoter, loss of function of the DMD gene, and inactivation of the tumor suppressor BAP-1. Studies of DNA methylation patterns in meningiomas have resulted in a novel and prognostically relevant meningioma subclassification schema. There have been major advances in our understanding of prognostically relevant genetic and epigenetic changes in meningioma which will hopefully allow for improvement in clinical trial design and the development of more effective therapies for meningioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.